JACKIE R SEE, M.D.
Medical Practice at Riviera Ct, Fullerton, CA

4820732, Apr 11, 1989

Apr 4, 1986

6/848233

William E. Shell - Los Angeles CA
Jackie R. See - Fullerton CA

The Upjohn Company - Kalamazoo MI

A61K 3119, A61K 31557

514573

A method for reducing dysfunction in angioplasty procedures and particularly, in myocardial angioplasty procedures in human beings is desired. The method involves the introduction of a selected amount of intra-arterial prostaglandin compound into an artery, such as a coronary artery, in which an angioplasty procedure is to occur. The prostaglandin compound will provide cyto-protection and provide antithrombotic effects and antiplatelet effects and antispasmatic effects. The prostaglandin compound is administered in a pharmacological amount, that is, an amount substantially greater than the prostaglandin which would be generated by a normal myocardial artery when insulated and thus, constitutes an administration substantially greater than an amount which would be administered in a replacement therapy. A composition is also provided for reducing dysfunction in angioplasty procedures and comprises a selected amount of a carrier and a prostaglandin compound carried in a specified amount and which carrier does not alter the prostaglandin compound and releases the prostaglandin compound at a rate sufficient to dilate blood vessels to thereby produce the required efficacy. A prepackaged combination of components provides for the complete administration of the prostaglandin compound before, during and after the angioplasty procedure.

4955878, Sep 11, 1990

Dec 8, 1988

7/281430

Jackie R. See - Fullerton CA
William E. Shell - Los Angeles CA

Biotechnology, Inc. - Los Angeles CA

A61M 500

604181

A kit for preventing or treating arterial dysfunction resulting from an angioplasty procedure and particularly, in myocardial angioplasty procedures in human beings. The kit provides the materials necessary to introduce a selected amount of an intraarterial prostaglandin compound into an artery, such as a coronary artery, in which an angioplasty procedure is to occur and an intravenous prostaglandin compound. The prostaglandin compound will provide cyto-protection and provide antithrombotic effects and antiplatelet effects and antispasmatic effects. A composition is also provided for reducing dysfunction in angioplasty procedures and comprises a selected amount of a carrier and a prostaglandin compound carried in a specified amount and which carrier does not alter the prostaglandin compound and releases the prostaglandin compound at a rate sufficient to dilate blood vessels to thereby produce the required efficacy. The kit is a prepackaged combination of components which provides for the complete administration of the prostaglandin compound before, during and after the angioplasty procedure.

2004025, Dec 23, 2004

Apr 8, 2004

10/821691

Jackie See - Fullerton CA, US
Darryl See - Laguna Niguel CA, US

Oral Vaccine Technologies, Inc.

A61K039/00, A61K009/127

424/450000, 424/184100

A method is provided for inducing a systemic immune response to an antigen. The method comprises providing a liposomal preparation comprising lyophilized liposomes containing at least one antigen. The liposomes have at least two sizes, before lyophilization, selected from small liposomes having a size, before lyophilization, of from about 20 nm to about 1 micron, medium liposomes having a size, before lyophilization, of from about 1 micron to about 3 microns, and large liposomes having a size, before lyophilization, of from about 3 microns to about 20 microns. An effective amount of the liposomal preparation is administered to a mammal, whereby sufficient antigen containing liposomes are absorbed in the Peyer's patches of the gut of the mammal and are taken up by macrophages in the Peyer's patches to stimulate a systemic immune response.

4616658, Oct 14, 1986

Feb 27, 1985

6/706151

William Shell - Beverly Hills CA
Jackie R. See - Fullerton CA

A61B 502

128691

A safe and inexpensive method of measuring blood flow in experimental animals using non-radioactively labeled microspheres is provided. The microspheres may be comprised of a variety of materials, including latex and agarose, and may be labeled with colored dyes or by linkage to enzymes, plant enzymes being preferred because they do not occur naturally in an animal's system. After injection and circulation of the microspheres throughout the animal's system, blood flow to particular tissue may be measured by counting the number of microspheres in the tissue sample, the initial number of microspheres in the animal's blood stream having been measured shortly after injection. In the case of microspheres labeled with colored dyes, the spheres may be counted in tissue either after separation from the tissue or while still trapped in the tissue's capillaries. Techniques for separating the microspheres from blood and tissue are also provided.

5747464, May 5, 1998

Jul 23, 1996

8/685209

Jackie Ray See - Fullerton CA

Bio-Sphere Technology, Inc. - Reno NV

A61K 31705, A61K 31715, C08B 3706

514 26

A composition for inhibiting absorption of fat and cholesterol from the gut and a method for making and using the composition. The composition comprises. beta. -sitosterol bound irreversibly to pectin to form a. beta. -sitosterol/pectin complex.

6046240, Apr 4, 2000

Apr 28, 1999

9/301023

Jackie R. See - Fullerton CA

Harvard Scientific Corporation - Reno NV

A61K 3119

514573

A method for treating female sexual dysfunction or for female sexual enhancement comprises administering to the vagina a composition comprising a prostanoid compound having a vasodilating effect in a pharmaceutically acceptable vehicle. The amount of prostanoid compound administered ranges from about 0. 05 mg to about 3 mg, and preferably from about 0. 125 mg to about 1 mg. Preferably the prostanoid compound is prostaglandin E-1 and the pharmaceutically acceptable vehicle is methylcellulose.

2006029, Dec 28, 2006

Jun 9, 2006

11/450187

Jackie See - Fullerton CA, US
Mark See - Fullerton CA, US

E21B 43/248

299002000

A system for extracting crude oil is discussed herein. The system includes a main shaft and one or more horizontal drifts extending from the base of the main shaft, which are located subjacent or below a reservoir trap or oil formation. A plurality of production boreholes are drilled upwardly from the horizontal drift towards the reservoir trap to gather the oil mixture and direct it to flow, either by gravity or from reservoir pressure at an angle towards the drifts below the formation. A manifold or distribution system located in the one or more horizontal drifts collect flow from the plurality of production boreholes. The collected flow is either pumped or lifted to the surface for separation, treatment, and/or processing or alternatively treated before pumped or lifted to the surface.

2004003, Feb 12, 2004

Apr 3, 2003

10/406748

Jackie See - Fullerton CA, US

A61B008/14

600/458000

A method for imaging diseased tissue is provided. The method provides delivering to the diseased tissue a liposomal imaging agent comprising liposomes containing an imaging agent. The liposomal imaging agent is bound to an antibody by an antigenic linker so that the antibody binds the liposomal imaging agent to the diseased tissue. The liposomes are broken to release the imaging agent using a catheter, and the imaging agent is viewed using an imaging technique. The tissue can also be treated by delivering a therapeutic agent to the tissue using the catheter, for example, within the liposomes of the liposomal imaging agent.

8313477, Nov 20, 2012

Mar 4, 2011

13/041307

Jackie R. See - Fullerton CA, US
Carl J. Buczek - Santa Ana CA, US
John W. Matthews - Newport Beach CA, US

A61M 31/00

604522

A device and methods for the real-time monitoring of stem cells in a stem cell transplant. The device comprises a linear member and particle detection device configured to occupy the lumen of a catheter while the catheter is in place to administer a stem cell transplant to a delivery site in the body of a patient. Monitoring of the stem cells permits the device to provide signals to a computer processor for the determination of one or more characteristics of stem cells in the stem cell transplant.